Melanoma Global Clinical Trials Review, H2, 2017

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report

Published: December 15, 2017 Report Code: GDHC4767CTIDB-ST

Select Item

GlobalData's clinical trial report, “Melanoma Global Clinical Trials Review, H2, 2017" provides an overview of Melanoma clinical trials scenario. This report provides top line data relating to the clinical trials on Melanoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global clinical trials landscape

– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

– The Report provides enrollment trends for the past five years

– Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Bristol-Myers Squibb Co
F. Hoffmann-La Roche Ltd
Merck & Co Inc
Novartis AG
GlaxoSmithKline Plc
AstraZeneca Plc
Pfizer Inc
Sarah Cannon Research Institute LLC
Eisai Co Ltd
Amgen Inc

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Report Guidance 6

GlobalData Clinical Trials Report Coverage 7

Clinical Trials by Region 8

Clinical Trials and Average Enrollment by Country 9

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12

Top Five Countries Contributing to Clinical Trials in Europe 13

Top Countries Contributing to Clinical Trials in North America 14

Top Countries Contributing to Clinical Trials in Middle East and Africa 15

Top Five Countries Contributing to Clinical Trials in Central and South America 16

Clinical Trials by G7 Countries: Proportion of Melanoma to Oncology Clinical Trials 17

Clinical Trials by Phase in G7 Countries 19

Clinical Trials in G7 Countries by Trial Status 20

Clinical Trials by E7 Countries: Proportion of Melanoma to Oncology Clinical Trials 22

Clinical Trials by Phase in E7 Countries 23

Clinical Trials in E7 Countries by Trial Status 24

Clinical Trials by Phase 25

In Progress Trials by Phase 26

Clinical Trials by Trial Status 27

Clinical Trials by End Point Status 29

Subjects Recruited Over a Period of Time 30

Clinical Trials by Sponsor Type 31

Prominent Sponsors 32

Top Companies Participating in Melanoma Therapeutics Clinical Trials 34

Prominent Drugs 36

Latest Clinical Trials News on Melanoma 37

Dec 13, 2017: Enrollment of First Patient in Investigator-Initiated Clinical Trial for Telomelysin (OBP-301) – pembrolizumab combination therapy 37

Dec 11, 2017: Targovax announces that first combination trials with ONCOS-102 have passed their initial, planned, independent safety reviews 37

Dec 08, 2017: Novel Compound Restores Immune Response In Patients With Melanoma 37

Dec 05, 2017: Moleculin's WP1066 Drug gets FDA Brain Tumor IND Clearance 38

Nov 13, 2017: Combination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of Advanced Melanoma from a Phase 1b Clinical Trial 38

Nov 11, 2017: Syndax Announces Presentation of ENCORE 601 Data at Society for Immunotherapy of Cancer 32nd Annual Scientific Meeting 39

Nov 11, 2017: First Data for NKTR-214 in Combination with OPDIVO (nivolumab) for Patients with Stage IV Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers, Including Patients with PD-L1 Negative Status, Revealed at SITC 2017 39

Nov 10, 2017: X4 Pharmaceuticals Presents Clinical Data Demonstrating Immune Activation Through CXCR4 Pathway with X4P-001-IO 41

Nov 07, 2017: Initial Results from Phase 2 Study of CB-839 in Combination with Opdivo (nivolumab) to be Presented at the Society for Immunotherapy of Cancer Meeting 41

Nov 03, 2017: Adaptimmune to Present Update On MAGE-A4 Multi-tumor Study at Society for Immunotherapy of Cancer (SITC) Annual Meeting 42

Nov 03, 2017: First Clinical Data from Combination of X4P-001-IO and Keytruda (pembrolizumab) in Patients with Melanoma Will Be Presented at the Society for Immunotherapy of Cancer Annual Meeting 42

Oct 30, 2017: CBT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of its PD-L1 Immunotherapy Antibody, CBT-502 at the AACR-NCI-EORTC International Conference on Molecular Target and Cancer Therapeutics 43

Oct 30, 2017: Biohaven Announces First Patient Treated In Clinical Research Collaboration At Rutgers Cancer Institute 43

Oct 12, 2017: Philogen Announces Authorization from FDA of a Pivotal Registration Trial in USA for the Treatment of Resectable Melanoma 43

Clinical Trial Profile Snapshots 45

Appendix 1545

Abbreviations 1545

Definitions 1545

Research Methodology 1546

Secondary Research 1546

About GlobalData 1547

Contact Us 1547

Disclaimer 1547

Source 1548

Table

Melanoma Therapeutics, Global, Clinical Trials by Region, 2017* 8

Melanoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9

Melanoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11

Melanoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 12

Melanoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 13

Melanoma Therapeutics Clinical Trials, North America, Top Countries, 2017* 14

Melanoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 15

Melanoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 16

Proportion of Melanoma to Oncology Clinical Trials, G7 Countries (%), 2017* 17

Melanoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19

Melanoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20

Proportion of Melanoma to Oncology Clinical Trials, E7 Countries (%), 2017* 22

Melanoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 23

Melanoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 24

Melanoma Therapeutics, Global, Clinical Trials by Phase, 2017* 25

Melanoma Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 26

Melanoma Therapeutics, Global, Clinical Trials by Trial Status, 2017* 27

Melanoma Therapeutics Clinical Trials, Global, by End Point Status, 2017* 29

Melanoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 30

Melanoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 31

Melanoma Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 32

Melanoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 34

Melanoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 36

Figures

Melanoma Therapeutics, Global, Clinical Trials by Region (%), 2017* 8

Melanoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9

Melanoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11

Melanoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 12

Melanoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 13

Melanoma Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 14

Melanoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 15

Melanoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 16

Proportion of Melanoma to Oncology Clinical Trials, G7 Countries (%), 2017* 17

Melanoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19

Melanoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20

Proportion of Melanoma to Oncology Clinical Trials, E7 Countries (%), 2017* 22

Melanoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 23

Melanoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 24

Melanoma Therapeutics, Global, Clinical Trials by Phase (%), 2017* 25

Melanoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 26

Melanoma Therapeutics, Global, Clinical Trials by Trial Status, 2017* 27

Melanoma Therapeutics Clinical Trials, Global, by End Point Status, 2017* 29

Melanoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 30

Melanoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 31

Melanoma Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 32

Melanoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 34

Melanoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 36

GlobalData Methodology 1546

Frequently asked questions

Melanoma Global Clinical Trials Review, H2, 2017 standard reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Oncology reports
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Pharmaceuticals
New
Clinical Trials Scorecard for Investigations in 2023
$695 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Melanoma Global Clinical Trials Review, H2, 2017 in real time.

  • Access a live Melanoma Global Clinical Trials Review, H2, 2017 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more